Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 50-58 , January 2008

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma

Received 16 September 2006 ,Accepted 18 April 2007.

References 

  1. Schimmer AD, Jamal S, Messner H, et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant. 2000;26:859–864
  2. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry–matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–678
  3. Bierman PJ, Sweetenham JW, Loberiza FR, et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation. The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003;21:3744–3753
  4. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med. 1979;300:1068–1073
  5. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;15:2462–2465
  6. van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–3529
  7. Butcher BW, Collins RH. The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplant. 2005;36:1–17
  8. Peggs KS, Mackinnon S, Linch DC. The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol. 2005;128:153–168
  9. Russell NH, Byrne JL, Faulkner RD, et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36:437–441
  10. Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant. 2004;10:579–590
  11. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukemia. Blood. 2005;106:4389–4996
  12. Morris EC, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865–3871
  13. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100:3108–3114
  14. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004;103:790–795
  15. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32:28–35
  16. Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using reduced-intensity conditioning. Leukemia. 2003;17:841–848
  17. Mandingers CM, Verdonck LF, Meijerink JP, et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32:1159–1163
  18. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review 1975-2002. Bethesda, MD: National Cancer Institute; 2005;
  19. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756–762
  20. Kottardis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1 H prevents graft-versus-host disease after nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425
  21. Chakraverty R, Peggs KS, Chopra R, et al. Limiting transplantation-related mortality after unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078
  22. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease after allogeneic transplantation from HLA-identical sibling with antithymocyte globulin–based reduced-intensity preparative regimen. Blood. 2003;102:470–476
  23. Pérez-Simón JA, Kottardis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127
  24. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nomyeloablative stem cell transplantation: potential role of Campath-1 H in delaying immune reconstitution. Blood. 2002;99:4357–4363
  25. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions after reduced-intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103:1548–1556
  26. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–735
  27. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute–sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997
  28. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI-Sponsored International Working Group. J Clin Oncol. 1999;17:1244–1253
  29. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828
  30. Hart DP, Avivi I, Thomson KJ, et al. Use of 18F-FDG positron emission tomography after allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br J Haematol. 2005;128:1065–1069
  31. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188–2195
  32. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3166–3274
  33. McLoughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  34. Huss R, Deeg HJ, Gooley T, et al. Effect of MC on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant. 1996;18:767–776
  35. Walker H, Singer CR, Patterson J, et al. The significance of host haemopoietic cells detected by cytogenetic analysis of bone marrow from recipients of bone marrow transplants. Br J Haematol. 1986;62:385–391
  36. Petz LD, Yam P, Wallace RB, et al. Mixed haematopoietic chimerism after bone marrow transplantation for hematologic malignancies. Blood. 1987;70:1331–1337
  37. Schattenberg A, De Witte T, Salden M, et al. Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. Blood. 1989;73:1367–1373
  38. Pérez-Simón JA, Caballero D, Diaz-Campello M, et al. Chimerism and minimal residual disease monitoring after reduced-intensity conditioning (RIC) allogeneic transplantation. Leukemia. 2002;16:1423–1431
  39. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003
  40. Thiede C, Florek M, Bornhäuser M, et al. Rapid quantification of MC using multiplex amplification of short-tandem repeat markers and fluorescence detection. Bone Marrow Transplant. 1999;23:1055–1060
  41. Mapara MY, Kim Y-M, Wang S-P, et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 2002;100:1903–1909
  42. Baron F, Little MT, Storb R. Kinetics of engraftment after allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev. 2005;19:153–164
  43. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234–3241
  44. Petersen SL, Madsen HO, Ryder LP, et al. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day +14 as a predictor of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:337–346
  45. Mattsson J, Uzunel M, Brune M, et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2001;115:935–944

 An abstract of these data was presented at the American Society of Hematology Annual Meeting, Atlanta, 2005.

PII: S1083-8791(07)00461-2

doi: 10.1016/j.bbmt.2007.04.013

Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 50-58 , January 2008

Article Tools

* Image Usage & Resolution